AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge

Gene Therapy, Published online: 19 February 2021; doi:10.1038/s41434-021-00236-yAAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge

Source: Gene Therapy - February 19, 2021 Category: Genetics & Stem Cells Authors: Matthew M. Guilleman Brenna A. Y. Stevens Laura P. Van Lieshout Amira D. Rghei Yanlong Pei Lisa A. Santry Brad Thompson Sarah K. Wootton Source Type: research